Your session is about to expire
What is Inbrija
LevodopaThe Generic name of this drug
Treatment SummaryLevodopa is a medication used to treat Parkinson's Disease. It works by crossing the blood-brain barrier and converting into dopamine, a neurotransmitter responsible for movement. To prevent levodopa from being broken down too quickly, it is usually taken with a drug called carbidopa. The FDA approved the combination of levodopa and carbidopa as Sinemet in 1975.
Sinemetis the brand name
Inbrija Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Sinemet
Levodopa
1975
272
Approved as Treatment by the FDA
Levodopa, also called Sinemet, is approved by the FDA for 6 uses including manganese intoxication and Parkinsonism post encephalitic .manganese intoxication
Used to treat manganese intoxication in combination with Carbidopa
Parkinsonism post encephalitic
Used to treat Parkinsonism post encephalitic in combination with Carbidopa
Parkinson's Disease
Used to treat Parkinson's Disease (PD) in combination with Carbidopa
Parkinsonism
Used to treat Parkinsonism in combination with Carbidopa
Paralysis agitans
Used to treat Paralysis agitans in combination with Carbidopa
carbon monoxide intoxication
Used to treat carbon monoxide intoxication in combination with Carbidopa
Effectiveness
How Inbrija Affects PatientsLevodopa is designed to pass through the blood-brain barrier, while dopamine is not. To ensure that as much levodopa as possible reaches the brain, a dopa decarboxylase inhibitor is added to the drug. This stops it from being converted to dopamine outside of the blood-brain barrier. Once inside the blood-brain barrier, it is then converted to dopamine by another enzyme.
How Inbrija works in the bodyLevodopa passes through the blood-brain barrier and is converted into dopamine. This dopamine acts as a replacement for the dopamine that the brain is missing, and stimulates dopamine receptors.
When to interrupt dosage
The recommended amount of Inbrija is contingent upon the diagnosed condition, for instance manganese intoxication, Parkinson's Disease and Restless Legs Syndrome (RLS). The dosage likewise fluctuates as per the technique of delivery outlined in the table beneath.Condition
Dosage
Administration
Parkinsonism
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
advanced Motor fluctuations
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
carbon monoxide intoxication
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
manganese intoxication
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinson's Disease
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Restless Legs Syndrome (RLS)
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Paralysis agitans
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Parkinsonism post encephalitic
, 100.0 mg, 250.0 mg, 200.0 mg, 50.0 mg, 75.0 mg, 125.0 mg, 150.0 mg, 95.0 mg, 145.0 mg, 195.0 mg, 245.0 mg, 20.0 mg/mL, 175.0 mg, 42.0 mg, 33.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Enteral, Gel, Gel - Enteral, Capsule, extended release, Capsule, extended release - Oral, Suspension, Suspension - Enteral, Capsule, Capsule - Oral, Respiratory (inhalation), Capsule - Respiratory (inhalation)
Warnings
Inbrija ContraindicationsCondition
Risk Level
Notes
Malignant Neoplasms
Do Not Combine
Pulse Frequency
Do Not Combine
cutaneous lesions
Do Not Combine
Common Inbrija Drug Interactions
Drug Name
Risk Level
Description
Azelastine
Major
Levodopa may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Ethanol
Major
Levodopa may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Macimorelin
Major
The therapeutic efficacy of Macimorelin can be decreased when used in combination with Levodopa.
Methylene blue
Major
Levodopa may increase the serotonergic activities of Methylene blue.
Mirtazapine
Major
Levodopa may increase the serotonergic activities of Mirtazapine.
Inbrija Toxicity & Overdose RiskThere is no known safety information regarding levodopa use during pregnancy. Rabbit studies have shown that taking levodopa and carbidopa can lead to smaller litters and birth defects. Levodopa may reduce the production of prolactin and interfere with breastfeeding. It is present in human breast milk and so nursing mothers should be warned of the potential effects before taking levodopa. There is also insufficient data about the use of levodopa in children under 18 years old. People over 65 years of age may be more likely to experience side effects when taking levodopa, but it should not automatically exclude them from treatment.
Inbrija Novel Uses: Which Conditions Have a Clinical Trial Featuring Inbrija?
48 active studies are currently underway to assess the potential of Inbrija to provide relief from Parkinson's Disease, Parkinsonism and carbon monoxide intoxication.Condition
Clinical Trials
Trial Phases
Parkinson's Disease
46 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Phase 2, Early Phase 1
manganese intoxication
0 Actively Recruiting
Paralysis agitans
0 Actively Recruiting
Restless Legs Syndrome (RLS)
1 Actively Recruiting
Not Applicable
advanced Motor fluctuations
0 Actively Recruiting
Parkinsonism post encephalitic
0 Actively Recruiting
Parkinsonism
3 Actively Recruiting
Phase 4
carbon monoxide intoxication
0 Actively Recruiting
Inbrija Reviews: What are patients saying about Inbrija?
5Patient Review
1/15/2020 Super easy to set up, and it doesn't make me gag or cough excessively like some other treatments I've tried. Really helps me out when I need it!
4.3Patient Review
10/4/2019 Though it's tough to inhale, this medication works quickly and gets me through my off times. I take Rytary 4 x 4. Right now, I'm trying it out to see how much it will cost.
4.3Patient Review
2/1/2022 I've had PD for 22 years and Inbrija has been a real godsend. I'm careful to not overuse it, but it's still tempting because it works so well. That said, its effectiveness does seem to wane the more you use it.
3.7Patient Review
9/19/2019 You might cough a lot and have a histamine reaction the first time you use this, so be prepared. It's not pleasant, but it does work.
2.3Patient Review
9/25/2019 The idea behind this treatment is good, but the delivery method is very ineffective. It's hard to inhale the powder and I end up coughing for 15 minutes afterwards. Not worth it for me.
2.3Patient Review
10/10/2019 Inhaling this powder will cause an intense gag reflex or coughing. It's difficult to use as a result; I often accidentally coughed it back up after inhaling. However, the product did seem to work well after I took a double dose of the recommended amount.
2.3Patient Review
8/9/2019 This medication is effective in treating my off periods, but the process of taking it is really unpleasant. Inhaling the medicine feels like breathing in a dusty sandstorm.
1.7Patient Review
10/10/2019 Inhaling this powder is very difficult, as most of it just ends up coating the inside of my mouth. It also makes me cough and gag. I haven't noticed any difference in my tremor or gait after taking Inbrija.
1.3Patient Review
7/4/2021 I'm really disappointed in this treatment. After following all the set-up steps, I began coughing and choking when I inhaled. My throat is now irritated and I hope I don't get pneumonitis from this...
1Patient Review
7/4/2021 Terrible! I followed the instructions to a tee and still found myself choking and coughing. My throat is now irritated on top of it all. I really hope I don't get pneumonitis from this.
Patient Q&A Section about inbrija
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What drug class is Inbrija?
"Inbrija is a drug that is used to treat Parkinson's disease. It belongs to a class of drugs called Antiparkinson Agents, Dopamine Precursors. It is not known if Inbrija is safe and effective in children."
Answered by AI
What happens if you swallow Inbrija?
"If you cough or feel like you're choking after using this medication, or if you experience any of the following side effects, call your doctor or pharmacist. These side effects include dizziness, lightheadedness, nausea, trouble sleeping, unusual dreams, a stuffy or runny nose, a sore throat, or a fever."
Answered by AI
How long does it take for Inbrija to work?
"The effects of INBRIJA tended to last for at least 3 hours.
INBRIJA has been shown to start working as early as 10 minutes in large clinical trials, with meaningful improvement in motor symptoms seen by 30 minutes. The effects of INBRIJA tended to last for at least 3 hours."
Answered by AI
What is Inbrija used for?
"Indication: INBRIJA is a prescription medicine used to treat OFF episodes in adults with Parkinson's who are taking regular carbidopa/levodopa medication. INBRIJA does not replace regular carbidopa/levodopa medication."
Answered by AI